Repros Therapeutics Stock Rating Reaffirmed by Bank of America Corp. (RPRX)
Repros Therapeutics (NASDAQ:RPRX)‘s stock had its “buy” rating reiterated by equities researchers at Bank of America Corp. in a research report issued on Wednesday, American Banking & Market News reports. They currently have a $35.00 price target on the stock, up from their previous price target of $25.00. Bank of America Corp.’s target price would suggest a potential upside of 46.75% from the company’s current price.
The analysts wrote, “Following positive top line phase 3 data (study ’302) for RPRX’s Androxal, we raised our estimated probability of approval to 90% (from 75%), lowered our assumed discount rate to 10% (from 11%) and now model faster uptake. The efficacy results from the ’302 and previously released ’301 trial along with six month safety data from the ’300 trial in our view strengthens the case to approve Androxal for low testosterone (low T) treatment. RPRX remains on-track to file for US approval in mid-2014. We now model risk-adjusted sales of $450mn in 2020 ($379mn prev.). Our peak 10% market penetration forecast for Androxal is unchanged and we note this assumption could be conservative (see page 2 for sensitivity analysis on market penetration rates). Our changes resulted in an increase of $10 to our DCF-derived PO. Our new PO is $35.”
Other equities research analysts have also recently issued reports about the stock. Analysts at Brean Capital reiterated a “buy” rating on shares of Repros Therapeutics (NASDAQ:RPRX) in a research note to investors on Tuesday.
Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Repros Therapeutics presently has a consensus rating of “Buy” and an average target price of $29.00.
Repros Therapeutics (NASDAQ:RPRX) opened at 23.85 on Wednesday. Repros Therapeutics has a 52 week low of $8.42 and a 52 week high of $28.30. The stock has a 50-day moving average of $20.59 and a 200-day moving average of $17.65. The company’s market cap is $548.6 million. Repros Therapeutics also saw unusually large options trading on Tuesday. Traders bought 40,053 call options on the company. This represents an increase of 796% compared to the average volume of 4,470 call options.
Repros Therapeutics (NASDAQ:RPRX) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.02. Analysts expect that Repros Therapeutics will post $-1.40 EPS for the current fiscal year.
Repros Therapeutics, Inc is a United States-based company that develops products and services for the management of reproductive health.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.